公开(公告)号：US20240216369A1

公开(公告)日：2024-07-04

申请号：US17755435

申请日：2020-10-30

Applicant: Novartis AG

Inventor： Martin BEIBEL ,  Beth BOROWSKY ,  Jang-Ho CHA ,  Thomas FALLER ,  Baltazar GOMEZ-MANCILLA ,  Caroline GUBSER KELLER ,  Marc LAISNEY ,  Wen LIN ,  Nicole RENAUD ,  Rajeev SIVASANKRAN

IPC: A61K31/501 ,  A61K9/00 ,  A61K9/08 ,  A61K45/06 ,  A61K47/40 ,  A61P25/28

CPC classification number: A61K31/501 ,  A61K9/0053 ,  A61K9/08 ,  A61K45/06 ,  A61K47/40 ,  A61P25/28

Abstract: Use of a splicing modulator for a treatment slowing progression of Huntington's disease.

公开(公告)号：US20240041853A1

公开(公告)日：2024-02-08

申请号：US18255423

申请日：2021-12-03

Applicant: Novartis AG

Inventor： Jang-Ho CHA ,  Thomas FALLER ,  Baltazar GOMEZ-MANCILLA ,  Dimitris PAPANICOLAOU ,  Carman-Gabriela SERBAN ,  Florian VON RAISON

IPC: A61K31/4439 ,  A61K45/06 ,  A61P25/24

CPC classification number: A61K31/4439 ,  A61K45/06 ,  A61P25/24

Abstract: The invention relates to a dosage regimen of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-NMDA receptor including, but not limited to, major depressive disorder, treatment resistant depression and suicidality. The invention also relates to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of major depressive disorder in patients with suicidal ideation with intent.